Published in Schweiz Med Wochenschr on December 16, 1989
Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet (1995) 2.29
The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol (1994) 2.04
Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest (1997) 1.71
Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem (1993) 1.57
Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol (2000) 1.53
Energy expenditure and substrates oxidative patterns, after glucose, fat or mixed load in normal weight subjects. Eur J Clin Nutr (1997) 1.39
Toxicologic evaluation of FK 506. Transplant Proc (1990) 1.36
Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Mol Med (Berl) (2001) 1.18
Mycobacterium haemophilum causing perihilar or cervical lymphadenitis in healthy children. J Pediatr (1992) 1.17
Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim Biophys Acta (1995) 1.16
Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J (1994) 1.15
Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis (1999) 1.12
Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol (1997) 1.12
Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J Lipid Res (2001) 1.12
Apolipoprotein B metabolism in homozygous familial hypercholesterolemia. J Lipid Res (1989) 1.09
Persistent pupillary membrane in basenji dogs. Vet Rec (1991) 1.08
Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis (2001) 1.08
2-Amino-4-phosphonobutyric acid as a glutamate antagonist on locust muscle. Nature (1976) 1.06
Asymptomatic bacteriuria in diabetes mellitus. N Engl J Med (1967) 1.05
A monoclonal anti-idiotypic antibody against anti-receptor antibodies from myasthenic sera. Eur J Immunol (1982) 1.02
Low density lipoprotein causes general cellular activation with increased phosphatidylinositol turnover and lipoprotein catabolism. Proc Natl Acad Sci U S A (1988) 1.00
Factors affecting the in-vitro development to blastocysts of bovine oocytes matured and fertilized in vitro. J Reprod Fertil (1991) 1.00
Differences in lipoprotein subfraction composition and distribution between type I diabetic men and control subjects. Diabetes (1990) 0.96
Relationship between plasma insulin levels and high density lipoprotein cholesterol levels in healthy men. Diabetologia (1981) 0.95
Characterization of a human high density lipoprotein-associated protein, NA1/NA2. Identity with SP-40,40, an inhibitor of complement-mediated cytolysis. Arterioscler Thromb (1991) 0.94
Differential effects of low density lipoproteins on insulin-like growth factor-1 (IGF-1) and IGF-1 receptor expression in vascular smooth muscle cells. J Biol Chem (2000) 0.94
Protein heterogeneity of lipoprotein particles containing apolipoprotein A-I without apolipoprotein A-II and apolipoprotein A-I with apolipoprotein A-II isolated from human plasma. J Lipid Res (1988) 0.90
Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes. Diabetologia (1994) 0.89
Monoclonal antibodies directed against the neurotransmitter binding site of nicotinic acetylcholine receptor. FEBS Lett (1980) 0.89
Heterogeneity in the properties of the trypanolytic factor in normal human serum. Mol Biochem Parasitol (1994) 0.87
Treatment of hyperlipoproteinemia (HLP) type II A with a new phenoxy-isobuturic acid derivative, procetofen. Int J Clin Pharmacol Biopharm (1979) 0.85
[Dyslipidemia in the diabetic patient. Recommendations of ALFEDIAM (French Language Association for the Study of Diabetes and Metabolic Diseases)]. Diabete Metab (1995) 0.85
Iron-ascorbic acid-induced oxidant stress and its quenching by paraoxonase 1 in HDL and the liver: comparison between humans and rats. J Cell Biochem (2005) 0.84
Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1. Diabetologia (2003) 0.83
Acute hyperinsulinemia and very-low-density and low-density lipoprotein subfractions in obese subjects. Am J Clin Nutr (2000) 0.83
Lipoprotein (a) and vascular disease in diabetic patients. Diabetologia (1995) 0.83
Immunoaffinity fractionation of high-density lipoprotein subclasses 2 and 3 using anti-apolipoprotein A-I and A-II immunosorbent gels. Biochim Biophys Acta (1989) 0.82
Iron excess, early glucose intolerance and impaired insulin secretion in idiopathic haemochromatosis. Eur J Clin Invest (1973) 0.81
Liver glycerokinase deficiency in man with hyperglycerolaemia and hypertriglyceridaemia. Eur J Clin Invest (1984) 0.81
HDL lipids in close relatives of coronary heart disease patients. Environmental and genetic influences. Atherosclerosis (1979) 0.81
Beneficial effect of hormone replacement therapy on weight loss in obese menopausal women. Maturitas (1999) 0.81
Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. Metabolism (2001) 0.81
Distribution of apolipoprotein E between free and A-II complexed forms in very-low- and high-density lipoproteins: functional implications. Biochim Biophys Acta (1991) 0.81
HDL particle associated proteins in plasma and cerebrospinal fluid: identification and partial sequencing. Appl Theor Electrophor (1988) 0.81
Associations between HDL oxidation and paraoxonase-1 and paraoxonase-1 gene polymorphisms in families affected by familial combined hyperlipidemia. Nutr Metab Cardiovasc Dis (2004) 0.81
European Lipoprotein Club: report of the 20th annual conference, Tutzing, 8-11 September 1997. Atherosclerosis (1998) 0.81
Metabolic effects of dietary fiber from dehulled soybeans in humans. Am J Clin Nutr (1983) 0.80
Angiotensin II promotes selective uptake of high density lipoprotein cholesterol esters in bovine adrenal glomerulosa and human adrenocortical carcinoma cells through induction of scavenger receptor class B type I. Endocrinology (2001) 0.80
Immunofractionation of high density lipoprotein subclasses 2 and 3. Similarities and differences of fractions isolated from male and female populations. Atherosclerosis (1990) 0.80
Isolation of a glutaminergic receptor fraction from locust muscle. Biochem Soc Trans (1977) 0.80
The paraoxonase PON1 promoter polymorphism C(-107)T is associated with increased serum glucose concentrations in non-diabetic patients. Diabetologia (2001) 0.79
The apolipoprotein epsilon2 allele and the severity of coronary artery disease in Type 2 diabetic patients. Diabet Med (2001) 0.79
Apolipoprotein E polymorphisms and mortality in Italian type 2 diabetic patients. Eur J Clin Invest (2003) 0.79
[Apoprotein E (apo E) phenotype and serum lipids in diabetics]. Schweiz Med Wochenschr (1987) 0.79
Phenotyping is an accurate means of analysing the principal apolipoprotein E isoforms. Clin Chim Acta (1994) 0.78
Postprandial lipemia differentially influences high density lipoprotein subpopulations LpAI and LpAI,AII. J Lipid Res (1994) 0.78
The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients. Diabetologia (1991) 0.78
Effects of short-term modest weight loss on fasting and post-prandial lipoprotein sub-fractions in type 2 diabetes mellitus patients. Diabetes Metab (2001) 0.78
Apolipoprotein E polymorphism as a risk factor for vascular disease in diabetic patients. Diabetes Care (1995) 0.78
High density lipoprotein cholesterol in male relatives of patients with coronary heart disease. Atherosclerosis (1979) 0.78
Acquired (secondary) forms of hypertriglyceridemia. Am J Cardiol (1991) 0.77
Characterization of iodinated derivatives of alpha-bungarotoxin. Hoppe Seylers Z Physiol Chem (1980) 0.77
Effects of morphine sulphate on pituitary-testicular morphology of rats. Toxicol Lett (1980) 0.77
HDL and coronary heart disease: a familial trend. Adv Exp Med Biol (1987) 0.77
Toxicological studies on 1-substituted-indazole-3-carboxylic acids. Chemotherapy (1981) 0.77
Underexpression of the apolipoprotein E4 isoform in an Italian population. Arterioscler Thromb (1993) 0.77
Factors influencing the low density lipoprotein profile in type 2 diabetic patients. Diabet Med (1995) 0.77
Apoprotein D in a healthy, male population and in male myocardial infarction patients and their male, first-degree relatives. Atherosclerosis (1986) 0.77
Lipoprotein(a) and retinopathy in IDDM and NIDDM patients. Diabetes Care (1997) 0.76
Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients. Nutr Metab Cardiovasc Dis (2009) 0.76
Injury-induced synthesis and release of apolipoprotein E and clusterin from rat neural cells. Eur J Neurosci (1996) 0.76
Decreased HDL cholesterol in prepubertal and pubertal children of CHD patients. Atherosclerosis (1980) 0.76
High-resolution two-dimensional protein electrophoresis of pathological plasma/serum. Appl Theor Electrophor (1991) 0.76
Gender differences in a type 2 (non-insulin-dependent) diabetic population with respect to apolipoprotein E phenotype frequencies. Diabetologia (1993) 0.76
HDL cholesterol levels in patients with myocardial infarction and their families. Atherosclerosis (1986) 0.76
Canine pituitary-testicular function in relation to toxicity testing. Toxicology (1979) 0.76
Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am J Ophthalmol (1994) 0.75
Marked changes of lipid levels during puberty in a patient with lipoprotein lipase deficiency. Eur J Pediatr (1997) 0.75
The (Ala-Val) mutation of methylenetetrahydrofolate reductase as a genetic risk factor for vascular disease in non-insulin-dependent diabetic patients. Am J Hum Genet (1997) 0.75
From biopsy to automatic diagnosis. Schweiz Med Wochenschr (1990) 0.75
Assessment of testicular toxicity in laboratory animals. Environ Health Perspect (1978) 0.75
[Dietary lipids and serum lipids in adolescents, based on the Geneva study of the precursors of atherosclerosis]. Soz Praventivmed (1984) 0.75
[Treatment of systemic lupus erythematosus with antimetabolites. Relations between the clinical course and immunological reactions]. Helv Med Acta (1967) 0.75
[Relation between HDL cholesterol and fasting glycemia in a normal population and a diabetic group]. Schweiz Med Wochenschr (1984) 0.75
[HDL-cholesterol and family incidence of coronary disease in the Genevan population]. Schweiz Med Wochenschr (1983) 0.75
Choriocarcinoma with intact pregnancy. Report of a case with review of the literature. Aust N Z J Obstet Gynaecol (1968) 0.75
Apparent lack of influence of the genetic drug oxidation status on plasma cholesterol concentration in man. Pharmacol Res Commun (1984) 0.75
A non-competitive enzyme-linked immunosorbent assay for measuring human plasma apolipoprotein B levels. Clin Chim Acta (1985) 0.75
[Reversible acquired acanthocytosis and hemolytic anemia associated with hypobetalipoproteinemia in a chronic alcoholic]. Schweiz Med Wochenschr (1983) 0.75
11C distribution in dogs visualized in situ after intravenous 11C-cyanide in high specific activity. Nucl Med (Stuttg) (1973) 0.75
Ambulatory medical care data: Milwaukee Model Cities survey of outpatient utilization. Med Care (1973) 0.75